Busting Popular Myths About Depression

Busting Popular Myths About Depression

This video from Big Think deals with some of the common myths surrounding depression. MORE: Could exercise help ALS patients with swallowing? Dr. Patricia Deldin from the University of Michigan Depression Center explains exactly what depression is and what it isn’t. Deldin shares that depression is an invisible illness that…

Explaining the Progression of ALS

This illustrated video from Stichting ALS Nederland briefly explains the neurodegenerative disease amyotrophic lateral sclerosis (ALS). MORE: Could exercise help ALS patients with swallowing? It explains the progression of the disease and how it affects patients. ALS causes the brain and spinal cord to stop transmitting signals to…

What’s the Difference Between ALS and MS?

There are some similarities between amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Both are diseases that attack the central nervous system, affecting the muscles and how you move your body. MORE: Find out about the early symptoms of ALS. They also both causes scarring around nerve…

Israel’s BrainStorm Offers Encouraging Phase 2 Data on Stem-Cell Therapy NurOwn to Treat ALS

Israel’s BrainStorm Cell Therapeutics has announced positive top-line Phase 2 data on NurOwn, a customized stem-cell therapy technology to treat amyotrophic lateral sclerosis (ALS). BrainStorm has been developing and commercializing NurOwn in partnership with Ramot, the business engagement unit of Tel Aviv University. NurOwn enables the production of growth factors that…

ALS Journeys: Andy’s Final Goodbye

This video series by the Brattleboro Reformer follows Andy Leclaire’s journey with amyotrophic lateral sclerosis (ALS). In this particular episode, friends and family reflect on Andy’s life and his struggle with the disease. It focuses on how Andy’s loved ones are doing since he passed and the effect his death has had…

Potential Gene Therapy for Familial ALS to Enter Preclinical Testing, Voyager Says

Preclinical testing will soon begin in VY-SOD101, a compound seen as a potential treatment for a certain gene mutation found in people with familial amyotrophic lateral sclerosis (ALS).  Its developer,  Voyager Therapeutics, hopes to follow this work, if successful, with clinical trials in patients  in about two years. Patients with ALS typically develop weakness…